should glp-1 agonists be open access Frontiers Frontiers | GLP−1 receptor agonists

Ill probably have the opportunity to tell you more about it in upcoming posts

Poulose SM, Miller MG, Scott T, Shukitt-Hale B

Some patients have a preference for brand-name medications while others are comfortable with compounded versions

Since CagriSema already contains semaglutide 2.4 mg, transitioning from standalone semaglutide to CagriSema would theoretically be simpler, though clinical guidance on this transition is limited

Its the same reason why doctors dont prescribe us magnesium over prescription stool softeners, weight-bearing exercise instead of calcium injections for osteoporosis, or diet changes instead of cholesterol-lowering medication to prevent heart disease

The potential dangers of long-term use that have not manifested in short-term research remain ambiguous